Page results
-
RESPOND is a new rapid access, community-based screening and care planning system for all asylum-seeking families registered with a GP in North Central London.
-
We provide routine histopathological diagnoses using both standard techniques and advanced diagnostics including immunocytochemistry, fluoresent in-situ hybridisation (FISH), and polymerase chain…
-
This page answers common questions about cryotherapy.
-
Please see below for information relating to various vaccination services offered at UCLH. To check which vaccinations you’ve had in the past, view your GP record using your NHS account or…
-
The Inherited White Matter Disorders (IWMD) Diagnostic and Management Service is a formally commissioned highly specialised service. There are seven centres across England. There are three centres…
-
National Patient Safety Alert Babies and young children (under five years) or children with additional needs, vulnerable adults and pets can suffer serious injury if they ingest coin/button batteries…
-
The Royal National ENT and Eastman Dental Hospitals is one of the UK's largest hospitals for ENT hospital surgery and Audiovestibular Medicine and provides a wide range of services, from…
-
We wanted to let you know that Michelle and Sam at DigiBete will be doing a couple of online training sessions to help you set up your school care plan.
File results
-
FOI/2024/0371 - Acute myeloid leukaemia treatment
-
FOI/2024/0365 - Specialist clinical systems to manage patients and patient clinical notes
-
FOI/2024/0363 - Freedom of Information responses available for Mesh requests
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer